• No results found

Health-related quality of life after stem cell transplantation – The first year

N/A
N/A
Protected

Academic year: 2021

Share "Health-related quality of life after stem cell transplantation – The first year"

Copied!
2
0
0

Loading.... (view fulltext now)

Full text

(1)

Health-related quality of life after stem cell transplantation – The first year

Akademisk avhandling

som för avläggande av filosofie doktorsexamen vid Sahlgrenska Akademien vid Göteborgs Universitet kommer att offentligen försvaras i Hörsal 2118, Arvid Wallgrens Backe, Hus 2, Göteborg,

fredagen den 26 november 2010 kl. 13.00 av

Inger Andersson

Fakultetsopponent är Professor Karin Nordin

Institutionen för folkhälso- och vårdvetenskap, BMC, Uppsala Universitet

Avhandlingen baseras på följande delarbeten:

I Andersson I, Hjermstad M, Stockelberg D, Persson LO. Health-Related Quality of Life in stem cell transplantation. Clinical and psychometric validation of the questionnaire module, High Dose Chemotherapy (HDC-19). Acta Oncol. 2008;47:275-85.

II Andersson I, Ahlberg K, Stockelberg D, Brune M,Persson LO. Health-related quality of life in patients undergoing allogeneic stem cell transplantation following reduced intensity conditioning versus myeloablative conditioning. Cancer Nurs. 2009;32:325-34.

III Andersson I, Ahlberg K, Stockelberg D,Persson LO. Patients´ perception of health related quality of life during the first year after autologous and allogeneic stem cell transplantation.

Eur J Cancer Care. Epub 2010 Mar 23.

IV Life after stem cell transplantation – patient’s perception of symptom, function and quality of life. (Submitted for publication)

Artikel I-III publiceras med tillstånd från respektive tidskrift

(2)

Health-related quality of life after stem cell transplantation – The first year

Inger Andersson

Institute of Health and Care Sciences at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Abstract

High-Dose Chemotherapy (HDC) followed by Stem Cell Transplantation (SCT) has been proven to be beneficial for a variety of haematological diseases, solid tumours and immune disorders. Despite improved care and treatment, SCT continues to produce significant long-term complications with impaired functioning and distressing symptoms. In this thesis the overall aim was to improve our knowledge about how SCT patients experience different types of transplantations and the effect it may have on their Health-Related Quality of Life (HRQoL) during the first year after SCT. Semi structured interviews were performed and two questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C30) and the module, High-Dose- Chemotherapy (HDC-19), were administered. Health-related quality of life after allogeneic SCT following Reduced Intensity Conditioning (RIC) and MyeloAblative Conditioning (MAC) were compared. Both groups showed a similar pattern of development over time in functioning and symptoms, albeit more severe in the MAC group. One year after SCT there were no significant differences between the groups in global Quality of Life (QoL). However, RIC patients improved in global QoL back to baseline earlier compared to MAC patients. When allogeneic and autologous patients were compared, RIC patients seemed to recover in the same way as autologous patients and these two groups were closer in their scoring compared to MAC patients. The results emphasize the need to separate the two allogeneic groups when evaluating HRQoL after SCT. Symptoms related to the digestive system like; dry mouth, sore mouth, appetite loss and change of taste together with fatigue were among the most frequent reported symptoms throughout the SCT period for all three groups. In the MAC group, symptoms of dry mouth and change of taste even increased, and one year after SCT these symptoms were more pronounced compared to baseline. Four themes emerged from the data analysis of the interviews and illustrate how the participants described their life from discharge until one year after SCT; obstacles on the road to normality, to be part of a normal life, the chance to be cured overshadow everything and new values in life. The patients described that they felt restricted in life and had problems to manage the response from family and friends. Stem cell transplantation had changed their opportunities in life, meaning that plans for the future had to be altered, sometimes in a negative way. Stem cell transplantation is a demanding procedure that affects the patients HRQoL over a long period of time. Alleviation and management of distressing symptoms and impaired functioning are some of the most important tasks for the health care providers in order to contribute to a better health and life situation for SCT survivors.

Keywords: health-related quality of life, stem cell transplantation, myeloablative conditioning, reduced intensity conditioning, symptoms, functioning

ISBN 978-91-628-8179-5 Gothenburg 2010

References

Related documents

Compared to normative data from the general population, survivors three months after stroke reported poorer HRQoL, both as measured by the EQ5D5L index and the EQ VAS.. The

Health- related quality of life in patients undergoing allogeneic stem cell transplantation following reduced intensity conditioning versus myeloablative conditioning..

In order to help patients to remember not only DM, diaries may be used to contribute to  recollection.  Diaries  written  in  everyday  language  both  by 

Associations with psychosocial and biological factors, and use as patient reported outcome. in routine

Music Therapy – an Intervention Effecting Quality of Life and Health in Children going through Hematopoietic Stem Cell Transplantation.. THESIS FOR DOCTORAL

In scientific paper III we retrospectively investigated the impact of HSCT grafts with inferior quality on clinical outcome in 144 patients receiving peripheral blood stem cell

"High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control

Studies have shown that it takes approximately one year for patients undergoing autologous or allogeneic HSCT to improve their HRQL to the baseline value (64, 65) , and that